Clinical and preclinical features of eribulin-related peripheral neuropathy

Area of Science:

• Oncology
• Neuroscience
• Pharmacology

Background:

• Microtubule-targeting agents (MTAs) are crucial in cancer therapy but often cause chemotherapy-induced peripheral neurotoxicity (CIPN).
• Eribulin, a halichondrin-class antineoplastic drug, exhibits high antimitotic activity against metastatic breast cancer and liposarcoma.
• Clinical data indicate eribulin is associated with a lower incidence of severe peripheral neuropathy compared to other MTAs.

Purpose of the Study:

• To review recent clinical and preclinical literature on eribulin.
• To elucidate the molecular mechanisms underlying eribulin's favorable neurotoxic profile.
• To discuss insights into CIPN pathogenesis derived from eribulin-related neuropathy models.

Main Methods:

• Literature review of clinical trial data and preclinical studies on eribulin.
• Analysis of animal models that reproduce eribulin-induced neuropathy.
• In vivo characterization of eribulin-related CIPN, including functional, symptomatic, and morphological assessments.

Main Results:

• Eribulin demonstrates a distinct neuropathologic induction mechanism compared to other MTAs.
• Animal models successfully replicate eribulin-related neuropathy, aiding in CIPN research.
• Evidence suggests unique molecular events contribute to eribulin's reduced neurotoxicity.

Conclusions:

• Eribulin's favorable neurotoxic profile is linked to specific molecular mechanisms.
• Preclinical models are valuable tools for investigating eribulin-induced CIPN.
• Understanding these mechanisms can inform the development of safer anti-cancer therapies.